Daxor Corp (DXR)
NASDAQ:DXR
Top Page
Daxor
(NASDAQ:DXR)
Select Model
Select Model
Rating:56Neutral
Price Target:
$9.50
▲(0.42% Upside)
Action:ReiteratedDate:04/07/26
The score is driven by DXR’s strong, low-debt balance sheet but tempered by weak and volatile cash flow and revenue instability. Technicals are notably bearish with the stock trading below major moving averages and negative MACD, while a low P/E provides some valuation support. A compliance-focused corporate filing is a minor positive but not a fundamental catalyst.
Positive Factors
Low leverage / strong balance sheet
Extremely low debt and a sizable equity cushion reduce solvency and refinancing risk, giving management durable optionality to invest in growth, fund operations, or withstand revenue shocks without urgent external financing. This improves multi-quarter resilience and strategic flexibility.
Negative Factors
Volatile revenue with sharp 2025 decline
Large swings in top-line undermine predictability of future cash flows and capacity to scale operations. A sharp post-spike decline suggests revenue is driven by episodic contracts or one-offs rather than stable demand, complicating multi-quarter planning and margin sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Extremely low debt and a sizable equity cushion reduce solvency and refinancing risk, giving management durable optionality to invest in growth, fund operations, or withstand revenue shocks without urgent external financing. This improves multi-quarter resilience and strategic flexibility.
Read all positive factors
Daxor (DXR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)1.99K
Price to Earnings (P/E)8.0
Beta (1Y)0.63
Revenue Growth-97.00%
EPS Growth3.43%
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.89
Shares Outstanding5,827,225
10 Day Avg. Volume865
30 Day Avg. Volume1,994
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.60
Price to Sales (P/S)146.07
P/FCF Ratio-121.66
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue318.27
Enterprise Value/Gross Profit-554.00
Enterprise Value/Ebitda5.01
Forecast
1Y Price Target
$22.50Price Target Upside137.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$11.90M
Daxor Business Overview & Revenue Model
Company Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective...
How the Company Makes Money
Daxor makes money primarily by commercializing its blood volume measurement platform and related services. Key revenue streams include: (1) sales or placements of BVA blood volume analysis systems and associated components used by hospitals and cl...
Daxor Earnings Call Summary
Earnings Call Date:Mar 06, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Positive
The earnings call presented a robust performance with significant revenue growth, successful strategic acquisitions, and expanded clinical partnerships. Despite a delay in FDA approval and a decrease in unrealized appreciation, the company showcased strong momentum and promising developments for the future.Positive Updates
Increase in Net Asset Value
Daxor's net assets increased from $34,010,384 in 2023 to $36,789,893 in 2024, reflecting a rise in net asset value per share from $7.08 to $7.25.
Negative Updates
Net Decrease in Unrealized Appreciation
There was a net decrease of $1,148,350 in the unrealized appreciation on investments due to the sale of positions with prior significant unrealized gains.
Read all updates
Q4-2024 Updates
Positive
Negative
Increase in Net Asset Value
Daxor's net assets increased from $34,010,384 in 2023 to $36,789,893 in 2024, reflecting a rise in net asset value per share from $7.08 to $7.25.
Read all positive updates
Company Guidance
During the Daxor Corporation Conference Call for the 2024 fiscal year, management provided several key financial and operational metrics. As of December 31st, 2024, the company's net assets increased to $36,789,893 or $7.25 per share, compared to $34,010,384 or $7.08 per share at the end of 2023. The company's net income included net dividend income of $104,115 and net realized gains on investments of $1,359,163, offset by a net decrease in unrealized appreciation of $1,148,350. The company invested $1,614,124 into its operating division for research and development, sales, and production facilities in anticipation of a 2025 product launch. Additionally, Daxor achieved a cash flow breakeven in early 2025, excluding costs related to stock-based compensation, depreciation, amortization, or CapEx. Revenue increased by 116.5% from 2023 to 2024, with a further year-on-year increase of over 100% in the first two months of 2025. The company also reported significant clinical progress with the adoption of its Blood Volume Analyzer (BVA) technology across various medical disciplines, laying the groundwork for further growth and innovation in healthcare solutions.Daxor Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
84
Very Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 503.42K | 2.13M | 34.59M | -353.36K | -2.62M |
| Gross Profit | 188.74K | 2.13M | 34.41M | -1.44M | -3.62M |
| EBITDA | 9.19M | 2.06M | 329.74K | 6.11M | 4.75M |
| Net Income | 9.17M | 536.33K | 280.64K | 5.18M | 4.75M |
Balance Sheet | |||||
| Total Assets | 46.01M | 36.63M | 34.87M | 30.26M | 24.98M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 710.70K |
| Total Debt | 112.00K | 729.97K | 755.66K | 1.23M | 3.02M |
| Total Liabilities | 122.59K | 840.30K | 858.76K | 1.29M | 3.83M |
| Stockholders Equity | 45.89M | 35.79M | 34.01M | 28.97M | 21.15M |
Cash Flow | |||||
| Free Cash Flow | -604.42K | 25.69K | -3.66M | -769.30K | -2.76M |
| Operating Cash Flow | -604.42K | 25.69K | -3.66M | -769.30K | -2.76M |
| Investing Cash Flow | 1.18M | 1.94M | 2.75M | 2.69M | 74.76K |
| Financing Cash Flow | -570.94K | -25.69K | 3.66M | 58.60K | 2.85M |
Daxor Technical Analysis
Negative
9.46
Price Trends
11.30
Negative
12.28
Negative
11.82
Negative
Market Momentum
-0.65
Positive
33.57
Neutral
41.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXR, the sentiment is Negative. The current price of 9.46 is below the 20-day moving average (MA) of 10.17, below the 50-day MA of 11.30, and below the 200-day MA of 11.82, indicating a bearish trend. The MACD of -0.65 indicates Positive momentum. The RSI at 33.57 is Neutral, neither overbought nor oversold. The STOCH value of 41.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DXR.
Daxor Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $165.04M | 14.29 | 29.25% | ― | 23.65% | 120.84% | |
66 Neutral | $4.06B | 40.58 | 8.52% | ― | 11.49% | -2.89% | |
56 Neutral | ― | 8.02 | 22.50% | ― | -97.00% | 3.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $22.13M | -5.14 | -164.78% | ― | 0.59% | -39.76% | |
42 Neutral | $23.98M | -1.44 | -534.91% | ― | 63.53% | 12.49% |
* Healthcare Sector Average
DXR
Daxor
9.47
1.42
17.62%
MMSI
Merit Medical Systems
68.26
-23.78
-25.84%
PDEX
Pro-Dex
51.48
-11.75
-18.58%
MLSS
Milestone Scientific
0.28
-0.63
-69.44%
FEMY
Femasys
0.40
-0.74
-65.18%
Daxor Corporate Events
Regulatory Filings and Compliance
Daxor Files Legal Opinion Affirming Validity of Stock
Positive
Jan 26, 2026
Daxor filed a legal opinion from Foley Lardner LLP regarding the legality of its common stock, indicating that the company has obtained formal legal validation for the issuance or status of its shares. This filing helps reinforce regulatory compl...
Other
Daxor Releases Updated Investor Presentation to Public Markets
Neutral
Jan 23, 2026
Daxor Corporation disclosed that it has made its current investor presentation publicly available, without providing additional operational, financial, or strategic details in the accompanying text. The release signals an effort to update and enga...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.